14,240 Shares in Amgen Inc. $AMGN Purchased by Kimelman & Baird LLC

Kimelman & Baird LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 14,240 shares of the medical research company’s stock, valued at approximately $5,157,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Roman Butler Fullerton & Co. boosted its position in shares of Amgen by 1.4% during the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after buying an additional 27 shares during the period. High Note Wealth LLC increased its position in Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. raised its stake in Amgen by 0.7% during the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares in the last quarter. Verus Capital Partners LLC raised its stake in Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares in the last quarter. Finally, Destination Wealth Management boosted its position in Amgen by 2.1% during the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after acquiring an additional 29 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AMGN. The Goldman Sachs Group set a $389.00 price target on Amgen in a research note on Friday, June 5th. Weiss Ratings raised shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Canaccord Genuity Group increased their target price on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Morgan Stanley restated an “overweight” rating and set a $362.00 price target on shares of Amgen in a research report on Wednesday, August 19th. Finally, Citigroup upped their price target on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $380.43.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of Amgen stock opened at $432.42 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The company’s 50-day moving average price is $388.64 and its two-hundred day moving average price is $364.71. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $447.03. The stock has a market cap of $233.78 billion, a PE ratio of 26.88, a price-to-earnings-growth ratio of 3.16 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the company earned $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.92 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.